Accumulating evidence from multiple CVOTs for SGLT2 inhibitors and GLP-1R agonists has resulted in major excitement in the fields of cardiovascular endocrinology and diabetic cardiology, as these agents display strong signs of cardioprotection in people with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.